Mannheimia haemolytica lktA Specific Neutra™ Antibody Products

Are you grappling with prolonged vaccine development timelines or challenges in neutralizing Mannheimia haemolytica leukotoxin cytotoxicity? Creative Biolabs' M. haemolytica lktA specific Neutra™ antibodies leverage advanced phage display and epitope-specific engineering to deliver high-affinity, validated tools for rapid and precise targeting of lktA, enabling accelerated therapeutic and diagnostic breakthroughs.

Introduction to M. haemolytica lktA

Mannheimia haemolytica serotype 1 Leukotoxin (lktA) is a pore-forming cytotoxin central to the pathogenesis of Bovine Respiratory Disease Complex (BRDC), a leading cause of economic loss in livestock industries. This Gram-negative bacterium predominantly infects cattle, causing acute fibrinous pneumonia and systemic inflammation.

Fig.1 Proposed model for the internalization and infection of differentiated bovine bronchial epithelial cells (BBECs) by serotype A1 M. haemolytica.¹

• Basic Information

lktA belongs to the repeats-in-toxin (RTX) family, secreted via a type I secretion system. Its expression is upregulated during host infection, directly correlating with leukocyte lysis and endothelial damage.

• Structure

The toxin forms a β-barrel pore structure upon binding to host cell receptors like CD18. Structural studies reveal its modular organization: an N-terminal hydrophobic domain for membrane insertion and a C-terminal receptor-binding domain. Trimerization is essential for cytotoxic activity, enabling disruption of host cell membranes.

• Related Signaling Pathways

lktA activates pro-inflammatory pathways, including NF-κB and MAPK cascades, amplifying cytokine storms (e.g., IL-8, TNF-α). Concurrently, it suppresses apoptosis in neutrophils, prolonging inflammatory tissue damage.

• Pathologies

Infection triggers severe bronchopneumonia, often complicated by secondary bacterial invasions. Mortality rates escalate due to acute respiratory distress and systemic sepsis, particularly in stressed or immunocompromised cattle.

Applications of M. haemolytica lktA Neutralizing Antibodies

• Diagnostic Assay Development

Anti-lktA antibodies enable rapid detection of M. haemolytica in clinical samples via ELISA or lateral flow assays, critical for early outbreak containment. Their high specificity minimizes cross-reactivity with non-target RTX toxins, ensuring reliable field diagnostics.

• Therapeutic Candidate Screening

These antibodies serve as benchmarks for evaluating novel therapeutics, such as small-molecule inhibitors or phage-based therapies. Preclinical studies using bovine models confirm that passive immunization reduces lung lesion severity and bacterial load.

• Vaccine Efficacy Evaluation

Quantifying lktA-neutralizing antibody titers in vaccinated cattle provides a direct correlate of immune protection, streamlining vaccine development. The antibodies are integral to potency testing in compliance with OIE standards.

• Pathogenesis Research

Researchers utilize these tools to map lktA-host interactions, including receptor dynamics and intracellular signaling modulation. Such insights guide the development of targeted anti-virulence strategies.

Our Anti-M. haemolytica lktA Antibodies

Neutralizing antibodies targeting lktA block receptor binding or prevent pore formation, effectively mitigating cytotoxicity. Creative Biolabs' antibodies are validated for:

- High specificity: Engineered to recognize conformational epitopes critical for lktA trimerization.

- Cross-reactivity: Effective against multiple M. haemolytica serotypes through conserved domain targeting.

- Functional validation: Demonstrated >90% neutralization efficiency in bovine alveolar macrophage assays.

Creative Biolabs provides M. haemolytica lktA specific Neutra™ antibody products based on unmatched precision for diagnostic research and therapeutic research applications. With deep expertise in veterinary pathogen targeting, we empower your BRDC mitigation efforts.

Contact our team today to explore custom solutions for your projects.

REFERENCE

1. Cozens, Daniel, et al. "Pathogenic Mannheimia haemolytica invades differentiated bovine airway epithelial cells." Infection and immunity 87.6 (2019): 10-1128. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1128/iai.00078-19